̽����ѡ

I have several years of experience in neuroscience and pharmacological research. After completing my bachelor’s degree in 2001, I began my research career at Neuroscience Scarl, Cagliari University, Italy. I then pursued a Ph.D. in Neuroscience at the University of Cagliari (2007-2010), followed by a postdoctoral position at the University of Southern California, USA (2010-2012). In 2012, I was awarded a Marie Curie Postdoctoral Research Fellowship for the PET-BRAIN project, which I worked on until 2014. I have been working since 2014 and since 2022 in the position of Senior Research Specialist at the Division of Neurogeriatrics at ̽����ѡ. I have established an independent research program focused on identifying new target proteins involved in the biological mechanisms of Alzheimer’s disease.  Throughout my career, I have secured several national grants (including those from Olle Engkvists Stiftelse, Alzheimerfonden, Demensfonden, and Åhlén-Stiftelsen) as well as international grants from organizations such as the Alzheimer’s Association.

My research is based on characterizing new target proteins involved in the biological bases of Alzheimer's disease. In particular, I am studying the AD
pathophysiological role of the intramembrane signal peptide peptidase like 2b (SPPL2b). For this purpose, we use the new AD mouse model, the APP-knock-in mouse AppNL-G-F and the SPPL2b deficient mouse line. My research is also concerned with evaluating the role of the endocannabinoidergic system (ECS) in neurological-related disorders and the biological mechanisms by which ECS is involved in neurodegenerative diseases such as AD.

Funding: 

Alzheimer´s Association, Olle Engkvists Stiftelse, Gun & Bertil Stohnes Stiftelse, Demensfonden, Lindhés Advokatbyrå Stiftelse, Åhlén-stiftelsen, Stiftelsen för Gamla Tjänarinnor

Project team members:

Jack Badman

Eileen Mac Sweeney

Bjorn Bakker

Wenjun Li